J. Goldman & Co’s TriSalus Life Sciences TLSI Stock Holding History

J. Goldman & Co’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-187,020	Closed	-$1.81M	–	467
2021 Q2	$1.81M	Buy	+187,020	New	+$1.83M	0.07%	231

Other funds holding TLSI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

J. Goldman & Co's TLSI Position: Q3 2021 in Review

J. Goldman & Co sold out of TriSalus Life Sciences (TLSI) in Q3 2021, closing a stake of 187,020 shares — an estimated $1.81M sold.

J. Goldman & Co first reported a position in TLSI in Q2 2021 and held it in 1 quarter. The position peaked at $1.81M in Q2 2021. 66 funds tracked by Wall St. Rank hold TLSI as of Q3 2021.

J. Goldman & Co reported no remaining TriSalus Life Sciences position as of Q3 2021 after selling out during the quarter.
J. Goldman & Co sold 187,020 TriSalus Life Sciences shares in Q3 2021, an estimated $1.81M.
J. Goldman & Co first reported a position in TriSalus Life Sciences in Q2 2021 and held it in 1 quarter.
J. Goldman & Co's TriSalus Life Sciences position peaked at $1.81M in Q2 2021.
66 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2021.

Based on J. Goldman & Co's 13F filing for Q3 2021, filed 15 Nov 2021.